Revenue Recognition

3 Months Ended

Mar. 30, 2024

Revenue from Contract with Customer [Abstract]

Revenue Recognition

REVENUE RECOGNITION

The following is a summary of our net sales by category (in millions):

	Three Months Ended
	March 30, 2024		April 1, 2023
CSCA(1)
Upper Respiratory	$	130.3	$	153.7
Digestive Health	122.2		124.0
Nutrition	90.6		138.5
Pain and Sleep-Aids	82.6		103.4
Healthy Lifestyle	71.3		73.4
Oral Care	64.7		83.3
Skin Care	49.6		69.8
Women's Health	27.2		12.3
Vitamins, Minerals, and Supplements ("VMS")	4.2		4.5
Other CSCA(2)	1.4		0.8
Total CSCA	$	644.1	$	763.7
CSCI
Skin Care	$	114.7	$	83.4
Upper Respiratory	69.1		84.8
Healthy Lifestyle	64.6		66.4
Pain and Sleep-Aids	51.4		49.9
VMS	44.6		47.8
Women's Health	32.0		29.1
Oral Care	28.7		29.1
Digestive Health	9.5		8.8
Other CSCI(3)	23.3		18.8
Total CSCI	437.9		418.1
Total net sales	$	1,082.1	$	1,181.7

(1) We updated our global reporting product categories as a result of legacy Rx sales being moved out of Other CSCA and into respective categories. These product categories have been adjusted retroactively to reflect the changes and have no impact on historical financial position, results of operations, or cash flows.

(2) Consists primarily of product sales and royalty income related to supply and distribution agreements and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

(3) Consists primarily of our Rare Diseases business and other miscellaneous or otherwise uncategorized product lines and other adjustments, none of which is greater than 10% of the segment net sales.

While the majority of revenue is recognized at a point in time, certain of our product revenue is recognized over time. Customer contracts recognized over time exist predominately in contract manufacturing arrangements, which occur in both the CSCA and CSCI segments. Contract manufacturing revenue was $72.2 million for the three months ended March 30, 2024, and $90.0 million for the three months ended April 1, 2023.

We also recognize a portion of the store brand OTC product revenues in the CSCA segment on an over time basis; however, the timing difference between over time and point in time revenue recognition for store brand contracts is not significant due to the short time period between the customization of the product and shipment or delivery.

The following table provides information about contract assets from contracts with customers (in millions):

	Balance Sheet Location	March 30, 2024		December 31, 2023
Short-term contract assets	Prepaid expenses and other current assets	$	25.7	$	28.5

We generated net sales in the following geographic locations(1) (in millions):

	Three Months Ended
	March 30, 2024		April 1, 2023
U.S.	$	632.3	$	750.0
Europe(2)	419.7		407.3
All other countries(3)	30.1		24.4
Total net sales	$	1,082.1	$	1,181.7

(1) The net sales by geography are derived from the location of the entity that sells to a third party.

(2) Includes Ireland net sales of $4.3 million for the three months ended March 30, 2024, and $7.3 million for the three months ended April 1, 2023.

(3) Includes net sales generated primarily in Australia and Canada.